PE20060485A1 - Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits - Google Patents

Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits

Info

Publication number
PE20060485A1
PE20060485A1 PE2005000782A PE2005000782A PE20060485A1 PE 20060485 A1 PE20060485 A1 PE 20060485A1 PE 2005000782 A PE2005000782 A PE 2005000782A PE 2005000782 A PE2005000782 A PE 2005000782A PE 20060485 A1 PE20060485 A1 PE 20060485A1
Authority
PE
Peru
Prior art keywords
progesterone receptor
chloro
kits
receptor antagonists
contraceptive
Prior art date
Application number
PE2005000782A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Casey Cameron Mcomas
Michael Anthony Marella
Jay Edward Wrobel
Edward George Melenski
Andrew Fensome
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20060485A1 publication Critical patent/PE20060485A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA ANTICONCEPTIVA, QUE COMPRENDE UN ANTAGONISTA DEL RECEPTOR DE PROGESTERONA (RP), SELECCIONADO DE MIFEPRISTONA, ONAPRISTONA, LILOPRISTONA, ASOPRISINIL, CDB-2914, 3-CLORO-5-(4,4-DIMETIL-2-OXO-1,4-DIHIDRO-2H-BENZO[d][1,3]OXAZIN-6-IL)-BENZONITRILO O UN COMPUESTO DERIVADO DE INDOL-OXINDOL, ENTRE OTROS; EN EL CUAL DICHA COMPOSICION SE ADMINISTRA DURANTE 28 DIAS CONSECUTIVOS, DE ACUERDO CON LOS PASOS: a) UNA PRIMERA FASE DE 21 A 27 UNIDADES DE DOSIFICACION DIARIA DEL ANTAGONISTA DE RP; Y b) UNA SEGUNDA FASE DE 1 A 7 UNIDADES DE DOSIFICACION DIARIAS DE UN PLACEBO FARMACEUTICAMENTE ACEPTABLE. ADEMAS SE REFIERE A UN KIT QUE COMPRNDE DICHAS UNIDADES DE DOSIFICACION
PE2005000782A 2004-07-07 2005-07-06 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits PE20060485A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
PE20060485A1 true PE20060485A1 (es) 2006-06-24

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000782A PE20060485A1 (es) 2004-07-07 2005-07-06 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits

Country Status (20)

Country Link
US (1) US20060009509A1 (es)
EP (1) EP1773323A1 (es)
JP (1) JP2008505906A (es)
KR (1) KR20070039912A (es)
AR (1) AR049664A1 (es)
AU (1) AU2005271974A1 (es)
BR (1) BRPI0512993A (es)
CA (1) CA2571198A1 (es)
CR (1) CR8800A (es)
EC (1) ECSP077131A (es)
GT (1) GT200500186A (es)
IL (1) IL180238A0 (es)
MX (1) MXPA06014580A (es)
NO (1) NO20070377L (es)
PA (1) PA8638501A1 (es)
PE (1) PE20060485A1 (es)
RU (1) RU2006144069A (es)
SV (1) SV2006002166A (es)
TW (1) TW200605880A (es)
WO (1) WO2006017075A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
WO2006014476A1 (en) 2004-07-07 2006-02-09 Wyeth Cyclic progestin regimens and kits
BRPI0513141A (pt) 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
EP2073806B1 (en) 2006-10-12 2012-02-15 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
CN106928247A (zh) 2008-10-17 2017-07-07 泽农医药公司 螺羟吲哚化合物及其作为治疗剂的用途
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
LT2419108T (lt) 2009-04-14 2016-12-27 Laboratoire Hra Pharma Kontracepcijos pagal poreikį būdas
ES2538386T3 (es) 2009-06-18 2015-06-19 Pfizer Inc. Compuestos bicíclicos y tricíclicos como inhibidores de KAT II
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PE20170202A1 (es) 2009-10-14 2017-03-24 Xenon Pharmaceuticals Inc Metodos sinteticos para compuestos espiro-oxoindol
MA34083B1 (fr) 2010-02-26 2013-03-05 Xenon Pharmaceuticals Inc Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
MX2013005773A (es) 2010-12-01 2013-06-18 Pfizer Inhibidores de kat ii.
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
CA2905214A1 (en) * 2013-03-14 2014-09-18 Laboratoire Hra-Pharma Method for scheduling ovulation
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
MX2017016823A (es) 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
BRPI0512993A (pt) 2008-04-22
IL180238A0 (en) 2007-07-04
KR20070039912A (ko) 2007-04-13
MXPA06014580A (es) 2007-03-23
WO2006017075A1 (en) 2006-02-16
CA2571198A1 (en) 2006-02-16
TW200605880A (en) 2006-02-16
GT200500186A (es) 2006-03-02
NO20070377L (no) 2007-02-07
ECSP077131A (es) 2007-02-28
CR8800A (es) 2007-08-28
JP2008505906A (ja) 2008-02-28
RU2006144069A (ru) 2008-08-20
PA8638501A1 (es) 2006-07-03
SV2006002166A (es) 2006-05-09
AR049664A1 (es) 2006-08-23
US20060009509A1 (en) 2006-01-12
EP1773323A1 (en) 2007-04-18
AU2005271974A1 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
PE20060485A1 (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
ES2558030T3 (es) Método anticonceptivo oral multifásico de ciclo prolongado
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
EA200600964A1 (ru) Фармацевтический препарат для непрерывного гормонального лечения в течение периода времени более длительного, чем 21-28 дней, включающий две композиции эстрогена и/или прогестина
IL154988A0 (en) Pharmaceutical compositions containing a 5-ht3 receptor antagonist
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
PE20060378A1 (es) Regimenes y kits de progestina ciclica
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
AR013506A1 (es) Uso de una composicion farmaceutica para la manufactura de un medicamento para ser usado en el tratamiento de enfermedades de obstruccion pulmonarcronica y de un kit que comprende formoterol o una sal o solvato del mismo y budesonida
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
SG152257A1 (en) Topical preparation containing ambroxol
DE60301261D1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
AR056694A1 (es) Uso de valerato de estradiol en combinacion con dienogest para la terapia oral de la hemorragia uterina disfuncional unida con una anticoncepcion oral
PE20040670A1 (es) Nuevas composiciones farmaceuticas que contienen ambroxol y yoduro de isopropamida
UY28334A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrógenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas.
NO20072893L (no) Fast, peroralt prevensjonsmiddel
TR200301553A1 (tr) İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
NO20072687L (no) Farmasoytisk prevensjonspreparat
AR020559A1 (es) Compuestos n-oxidos de piridina triciclicos, agonistas de la vasopresina, composicion farmaceutica que los comprende y el uso de los mismos para lamanufactura de un medicamento.
ES2136198T3 (es) Composiciones rectales que contienen odansetron en forma de su base libre.
BRPI0302736B8 (pt) composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
EA200600120A1 (ru) ЧИСТЫЕ ИЗОМЕРЫ d-(17α)-13-ЭТИЛ-17-ГИДРОКСИ-18,19-ДИНОРПРЕГН-4-ЕН-20-ИН-3-ОН-3E И 3Z-ОКСИМОВ, СПОСОБ СИНТЕЗА СМЕСИ ИЗОМЕРОВ И ЧИСТЫХ ИЗОМЕРОВ

Legal Events

Date Code Title Description
FD Application declared void or lapsed